Literature DB >> 8546529

Determination of interstitial collagenase (MMP-1) in patients with rheumatoid arthritis.

S Maeda1, T Sawai, M Uzuki, Y Takahashi, H Omoto, M Seki, M Sakurai.   

Abstract

OBJECTIVES: To investigate whether interstitial collagenase (MMP-1) concentration in synovial fluid can be useful as a marker for disease activity in rheumatoid arthritis (RA), to determine the main route by which collagenase degrades the matrix of articular cartilage, and to investigate if an imbalance between metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMP) is responsible for the activity of MMPs in RA.
METHODS: Collagenase concentrations were measured in synovial fluid and paired serum samples using a specific sandwich enzyme linked immunosorbent assay. Collagenase activities were also assayed in synovial fluid samples. Synovial tissues obtained from the same patient were examined by immunohistochemical staining and the numbers of cells expressing collagenase were counted.
RESULTS: Collagenase concentrations in synovial fluid did not correlate with C reactive protein and collagenase levels in serum, but did correlate positively with the degree of synovial inflammation, and increased with increasing numbers of cells identified as expressing collagenase in synovial tissue. Collagenase activities did not correlate with TIMP-1 concentrations, but did correlate strongly with the ratios of collagenase concentration to TIMP-1 (r = 0.73).
CONCLUSION: The collagenase concentration in synovial fluid cannot be used as a marker for systemic disease activity, but can be used as a marker for the degree of synovial inflammation in the joint from which the sample is aspirated. In advanced RA, most of the collagenase is probably produced in synovial lining cells and released into synovial fluid, where it degrades the matrix of articular cartilage. An imbalance between MMP and TIMP may be of importance in the degradation of extracellular matrix of articular cartilage in RA.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8546529      PMCID: PMC1010062          DOI: 10.1136/ard.54.12.970

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  38 in total

1.  A latent collagenase from embryonic human skin explants.

Authors:  H Shinkai; Y Nagai
Journal:  J Biochem       Date:  1977-05       Impact factor: 3.387

2.  Metalloproteases of human articular cartilage that digest cartilage proteoglycan at neutral and acid pH.

Authors:  A I Sapolsky; H Keiser; D S Howell; J F Woessner
Journal:  J Clin Invest       Date:  1976-10       Impact factor: 14.808

3.  Evidence for the presence of a latent form of collagenase in human rheumatoid synovial fluid.

Authors:  S Abe; Y Nagai
Journal:  J Biochem       Date:  1972-05       Impact factor: 3.387

4.  Synovial collagenase and joint diseases: the significancy of latent collagenase with special reference to rheumatoid arthritis.

Authors:  S Abe; M Shinmei; Y Nagai
Journal:  J Biochem       Date:  1973-05       Impact factor: 3.387

5.  Human skin collagenase: isolation of precursor and active forms from both fibroblast and organ cultures.

Authors:  G P Stricklin; E A Bauer; J J Jeffrey; A Z Eisen
Journal:  Biochemistry       Date:  1977-04-19       Impact factor: 3.162

6.  The measurement of collagenase, tissue inhibitor of metalloproteinases (TIMP), and collagenase-TIMP complex in synovial fluids from patients with osteoarthritis and rheumatoid arthritis.

Authors:  I M Clark; L K Powell; S Ramsey; B L Hazleman; T E Cawston
Journal:  Arthritis Rheum       Date:  1993-03

7.  Collagenases in human synovial fluid.

Authors:  E D Harris; D R DiBona; S M Krane
Journal:  J Clin Invest       Date:  1969-11       Impact factor: 14.808

8.  Collagenase and collagenase inhibitors in osteoarthritic and normal cartilage.

Authors:  M G Ehrlich; H J Mankin; H Jones; R Wright; C Crispen; G Vigliani
Journal:  J Clin Invest       Date:  1977-02       Impact factor: 14.808

9.  Human collagenase: identification and characterization of an enzyme from rheumatoid synovium in culture.

Authors:  J M Evanson; J J Jeffrey; S M Krane
Journal:  Science       Date:  1967-10-27       Impact factor: 47.728

10.  Collagenase at sites of cartilage erosion in the rheumatoid joint.

Authors:  D E Woolley; M J Crossley; J M Evanson
Journal:  Arthritis Rheum       Date:  1977 Jul-Aug
View more
  16 in total

Review 1.  MMPs and rheumatoid synovial fibroblasts: Siamese twins in joint destruction?

Authors:  U Müller-Ladner; S Gay
Journal:  Ann Rheum Dis       Date:  2002-11       Impact factor: 19.103

Review 2.  Are fibroblasts involved in joint destruction?

Authors:  T Pap; I Meinecke; U Müller-Ladner; S Gay
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

3.  MMP protein and activity levels in synovial fluid from patients with joint injury, inflammatory arthritis, and osteoarthritis.

Authors:  I Tchetverikov; L S Lohmander; N Verzijl; T W J Huizinga; J M TeKoppele; R Hanemaaijer; J DeGroot
Journal:  Ann Rheum Dis       Date:  2005-05       Impact factor: 19.103

4.  Gliostatin/thymidine phosphorylase-regulated vascular endothelial growth-factor production in human fibroblast-like synoviocytes.

Authors:  Tomohiro Tanikawa; Yuko Waguri-Nagaya; Takuma Kusabe; Mineyoshi Aoyama; Kiyofumi Asai; Takanobu Otsuka
Journal:  Rheumatol Int       Date:  2006-11-14       Impact factor: 2.631

5.  Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage.

Authors:  R C Billinghurst; L Dahlberg; M Ionescu; A Reiner; R Bourne; C Rorabeck; P Mitchell; J Hambor; O Diekmann; H Tschesche; J Chen; H Van Wart; A R Poole
Journal:  J Clin Invest       Date:  1997-04-01       Impact factor: 14.808

6.  Local removal of phagocytic synovial lining cells by clodronate-liposomes decreases cartilage destruction during collagen type II arthritis.

Authors:  P L Van Lent; A E Holthuysen; N Van Rooijen; L B Van De Putte; W B Van Den Berg
Journal:  Ann Rheum Dis       Date:  1998-07       Impact factor: 19.103

7.  Human parvovirus B19 as a causative agent for rheumatoid arthritis.

Authors:  Y Takahashi; C Murai; S Shibata; Y Munakata; T Ishii; K Ishii; T Saitoh; T Sawai; K Sugamura; T Sasaki
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

8.  Matrix metalloproteinases-3, -8, -9 as markers of disease activity and joint damage progression in early rheumatoid arthritis.

Authors:  I Tchetverikov; L R Lard; J DeGroot; N Verzijl; J M TeKoppele; F C Breedveld; T W J Huizinga; R Hanemaaijer
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

9.  Matrix metalloproteinase protein expression profiles cannot distinguish between normal and early osteoarthritic synovial fluid.

Authors:  Bryan J Heard; Liam Martin; Jerome B Rattner; Cyril B Frank; David A Hart; Roman Krawetz
Journal:  BMC Musculoskelet Disord       Date:  2012-07-23       Impact factor: 2.362

Review 10.  Physiology and pathophysiology of matrix metalloproteases.

Authors:  T Klein; R Bischoff
Journal:  Amino Acids       Date:  2010-07-18       Impact factor: 3.520

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.